Multiple Myeloma PBMC
Powered by BiozAbout:Multiple Myeloma PBMC samples are collected from clinically confirmed myeloma donors, processed within 24 hours and cryopreserved in CryoStor CS10. Suited to BCMA, GPRC5D and SLAMF7 bispecific and CAR-T potency work, anti-CD38 ADCC and NK function assays, T-cell exhaustion immunophenotyping, and circulating clonal plasma cell detection. Stratification by disease phase, M-protein class and treatment exposure, with matched healthy controls.
About Multiple Myeloma PBMC
Multiple Myeloma PBMC for Tumour Immunology Research
Human Multiple Myeloma PBMC products are sourced from IRB-consented donors clinically diagnosed with multiple myeloma, processed within 24 hours of collection and cryopreserved in CryoStor® CS10 to preserve viability and function. These peripheral blood mononuclear cells enable study of immune evasion, effector-cell dysfunction and treatment resistance in a plasma-cell malignancy, and are available in cell counts from 5 million to 2 billion.
Why Multiple Myeloma PBMC for Tumour Immunology Research
Multiple myeloma is a neoplastic disorder of terminally differentiated plasma cells. Clonal plasma cells accumulate in the bone marrow and secrete a monoclonal immunoglobulin or free light chain, producing bone disease, renal impairment, anaemia and hypercalcaemia. It is a cancer, not an autoimmune disease, and its immunology is that of a tumour that both suppresses and is targeted by the host immune system.
- Plasma-cell lineage antigens — CD38, BCMA, SLAMF7 and GPRC5D define the malignant compartment and are the antigens behind the current wave of antibody, bispecific and CAR-T therapeutics.
- T-cell dysfunction and exhaustion — repeated antigen exposure and a suppressive marrow microenvironment drive inhibitory receptor expression and reduced effector capacity, which can be characterised directly in donor PBMCs.
- Immunosuppressive cell populations — regulatory T cells and myeloid-derived suppressor cells expand in myeloma and blunt anti-tumour responses.
- NK cell effector function — NK cells mediate antibody-dependent cellular cytotoxicity, the mechanism underlying anti-CD38 antibody therapy, and their function in disease-state donors differs from that of healthy cells.
- Circulating plasma cells and clonal detection — a subset of donors carries measurable circulating clonal plasma cells, supporting minimal-residual-disease and clonality workflows on peripheral blood.
- Cellular specimen advantage — because PBMCs are viable nucleated cells, flow cytometry, cytotoxicity assays, redirected-killing potency assays, single-cell transcriptomics and TCR repertoire work are all available; none of these are possible in a plasma or serum product.
Donor Stratification Available
- Disease phase — newly diagnosed, on-treatment, in remission, and relapsed or refractory donors
- Monoclonal protein class — IgG, IgA and light-chain-only disease, subject to documentation
- Precursor and related conditions — MGUS and smouldering myeloma donors as comparators where available
- Treatment exposure — proteasome inhibitor, immunomodulatory drug, anti-CD38 antibody, and post-autologous-transplant donors
- Cytogenetic risk category and demographics — where documented, plus age, sex assigned at birth and race/ethnicity
- Matched healthy controls available, drawn on the same protocol and matched for age, sex and ethnicity
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed multiple myeloma donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified multiple myeloma diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Disease phase and prior treatment context reported per lot where captured
- Additional multiple myeloma-specific data available upon request
Applications
- BCMA, GPRC5D and SLAMF7-directed bispecific and CAR-T potency assays
- Anti-CD38 antibody-dependent cellular cytotoxicity and NK effector function studies
- T-cell exhaustion and effector dysfunction immunophenotyping
- Regulatory T cell and myeloid-derived suppressor cell characterisation
- Autologous effector-cell sourcing for redirected-killing assay development
- Circulating clonal plasma cell detection and minimal-residual-disease workflow development
- Single-cell transcriptomic and proteomic profiling of the myeloma immune compartment
- Drug screening, resistance modelling and biomarker discovery in myeloma pathophysiology
Other Multiple Myeloma Specimen Types
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Multiple Myeloma PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. To compare collection formats or check wider availability, visit our human PBMCs page.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), PBMC
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human PBMC are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Multiple Myeloma PBMC with normal donor samples for comparison
Healthy Donor PBMCs
703 In Stock View InventoryNeed a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.